Norges Bank Buys Shares of 64,900 Keros Therapeutics, Inc. (NASDAQ:KROS)

Norges Bank bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 64,900 shares of the company's stock, valued at approximately $1,027,000. Norges Bank owned about 0.16% of Keros Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. AlphaQuest LLC boosted its stake in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Keros Therapeutics in the 4th quarter worth about $90,000. Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics during the 4th quarter worth about $99,000. China Universal Asset Management Co. Ltd. grew its stake in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after acquiring an additional 1,372 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in shares of Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after purchasing an additional 1,100 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on KROS. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. Wedbush reaffirmed a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.33.

Remove Ads

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.90% of the stock is owned by company insiders.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS traded up $0.35 during mid-day trading on Tuesday, hitting $13.09. The company had a trading volume of 1,084,541 shares, compared to its average volume of 771,709. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The firm has a market cap of $530.96 million, a P/E ratio of -2.51 and a beta of 1.39. The business's 50-day simple moving average is $10.94 and its 200-day simple moving average is $30.31.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.